Istavel 50mg (Sitagliptin)

Istavel 50mg (Sitagliptin): Comprehensive Overview

Generic Name: Sitagliptin phosphate

Brand Name: Istavel

Drug Class: Dipeptidyl Peptidase-4 (DPP-4) inhibitor

What is Sitagliptin?

Sitagliptin is an oral antihyperglycemic medication employed to treat the symptoms of type 2 diabetes mellitus. It is part of a group of medications known as DPP-4 inhibitors. These medications enhance blood sugar control by enhancing the body’s capacity to control glucose and insulin in response to food.

Mechanism of Action

Sitagliptin is a drug that works in the same way by blocking dipeptidyl Peptidase 4 (DPP-4), which reduces the incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).

• Through stopping DPP-4, sitagliptin raises levels of incretin, and this:
  • The stimulation of the release of insulin by pancreatic beta cells occurs by releasing glucose in a glucose-dependent manner
  • Inhibit the release of glucagon in Alpha cells (which lowers hepatic sugar production)

The result is an improvement in glycemic control without leading to severe low blood sugar levels.

Indications

Istavel (Sitagliptin) is indicated for:

• Diabetes mellitus type 2 in monotherapy (when both exercise and diet alone do not suffice)
• Together with other anti-diabetic agents, like metformin or sulfonylureas, or insulin
• Improve glycemic control and decrease HbA1c levels

4. Dosage and Administration

• Standard dose: 50 mg a day, in combination with or without food
• In some situations or countries where the dosage may be different, it can be 100 mg twice each day, but always adhere to the local guidelines for prescribing.
• Adjusting the dose may be required for patients with kidney impairment:
  • Mild renal impairment (eGFR ≥ 50 mL/min): no dose adjustment
  • Moderate renal impairment (eGFR 30-50 mL/min): 50 mg once daily
  • Severe renal impairment or ESRD (eGFR <30 mL/min): 25 mg once daily

Pharmacokinetics

• Absorption: Absorption is rapid and nearly complete, with peak plasma concentrations 1-4 hours after the dose
• Bioavailability: Approximately 87%
• Protein binding: Low (~38%)
• Half-life: ~12.4 hours
• Metabolism: Hepatic metabolism occurs minimally via CYP3A4 and CYP2C8
• Excretion: Primarily kidney-related (about 79% of the unchanged urine)

Side Effects

Generally well tolerated. Common side effects include:

• Nasopharyngitis (common cold symptoms)
• Headache
• Upper respiratory tract infection

Less common/serious side effects:

• Hypersensitivity reactions (angioedema, anaphylaxis, Stevens-Johnson syndrome – rare)
• Pancreatitis (rare but serious)
• Joint pain (arthralgia)
• Hypoglycemia (particularly when they are particularly when)
• Renal impairment (monitor kidney function periodically)

Contraindications

• Hypersensitivity is known to sitagliptin, or any other component in the formulation
• Not recommended for type 1 diabetes or for diabetic ketoacidosis

Precautions

• Take care when treating patients with kidney impairment and adjust dosage accordingly.
• Be aware of any signs that suggest pancreatitis (severe abdominal discomfort and nausea).
• Be cautious when combining with other hypoglycemic drugs to prevent hypoglycemia
• The data are not extensive on the use of this product in lactation or during pregnancy. make use of only if the benefits outweigh the risks
• Continuously check blood glucose and HbA1c levels to assess the effectiveness of your treatment

Drug Interactions

• Metformin: Commonly, they are used together; there are no significant interactions
• Sulfonylureas or insulin: Hyperglycemia is a risk that increases; dose adjustments might be required.
• CYP3A4 and CYP2C8 inhibitors: There was no clinical interaction of any significance. However, caution is advised
• Other DPP-4 inhibitors or GLP-1 agonists: Mixing is not advised

Patient Counseling Points

• Consume Istavel daily in the same order throughout the day, either with or without food
• Keep your diet in check and work out in accordance with the recommendations of your healthcare physician
• Look out for signs of low blood sugar (shakiness, shaking, sweating, fainting)
• If you observe any indication of an allergic reaction or pancreatitis, immediately
• Be sure to monitor your blood sugar levels regularly and make sure you attend any appointment for follow-ups

Summary Table